Projects / Programmes source: ARIS

Pharmaceutical biotechnology: Science for health

Research activity

Code Science Field Subfield
4.06.01  Biotechnical sciences  Biotechnology  Recombinant DNA technology 
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B000  Biomedical sciences   

Code Science Field
3.04  Medical and Health Sciences  Medical biotechnology 
3.01  Medical and Health Sciences  Basic medicine 
Biotechnology; Pharmacy; Cancer; Neurodegenerative diseases; Immune diseases; Proteases; Cathepsins; Cystatin; Phage display; Allergy; RNA; TDP-43, FUS; Cytotoxicity; NK cells; T cells; Mimotopes; Lactic acid bacteria; Therapy; Diagnosis; Nanotechnology
Evaluation (rules)
source: COBISS
Data for the last 5 years (citations for the last 10 years) on July 14, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  889  32,130  28,010  31.51 
Scopus  932  35,296  31,025  33.29 
Researchers (47)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  37466  PhD Ana Bajc Česnik  Neurobiology  Junior researcher  2019  17 
2.  58563  Karolina Belingar  Biochemistry and molecular biology  Junior researcher  2023 - 2024 
3.  24257  PhD Aleš Berlec  Pharmacy  Researcher  2019 - 2024  225 
4.  36454  PhD Maruša Bizjak  Biochemistry and molecular biology  Researcher  2022  31 
5.  53738  PhD Krištof Bozovičar  Pharmacy  Researcher  2022  33 
6.  37546  PhD Janja Božič  Medical sciences  Researcher  2019 - 2021  30 
7.  23598  PhD Tomaž Bratkovič  Pharmacy  Researcher  2019 - 2021  242 
8.  54687  Urša Čerček  Neurobiology  Junior researcher  2020 - 2024  29 
9.  15099  PhD Darko Černe  Pharmacy  Researcher  2019 - 2024  262 
10.  19785  PhD Bojan Doljak  Pharmacy  Researcher  2019 - 2024  263 
11.  58564  Anja Dremelj  Biotechnology  Junior researcher  2023 - 2024 
12.  55893  Selena Horvat  Pharmacy  Junior researcher  2022 - 2024  10 
13.  39198  PhD Tanja Jakoš  Biotechnology  Researcher  2019 - 2020  29 
14.  33406  PhD Nikolaja Janež  Biochemistry and molecular biology  Researcher  2020 - 2024  86 
15.  04648  PhD Janko Kos  Biotechnical sciences  Head  2019 - 2024  1,166 
16.  15460  PhD Samo Kreft  Pharmacy  Researcher  2019 - 2024  781 
17.  37497  PhD Nika Kruljec  Pharmacy  Junior researcher  2019  19 
18.  19649  PhD Marija Nika Lovšin  Microbiology and immunology  Researcher  2022 - 2024  126 
19.  25096  PhD Mojca Lunder  Pharmacy  Researcher  2019 - 2021  260 
20.  39147  PhD Mirjana Malnar  Neurobiology  Researcher  2019 - 2021  46 
21.  53777  Mateja Matjaž    Technical associate  2019 - 2024 
22.  36440  PhD Ana Mitrović  Pharmacy  Researcher  2019 - 2024  117 
23.  38774  Maša Močnik Roner    Technical associate  2019 
24.  32431  PhD Peter Molek  Pharmacy  Researcher  2019  52 
25.  21397  PhD Helena Motaln  Biochemistry and molecular biology  Researcher  2019 - 2024  208 
26.  56246  Jerneja Nimac  Neurobiology  Junior researcher  2022 - 2024  25 
27.  32693  PhD Jasna Omersel  Pharmacy  Researcher  2019 - 2021  89 
28.  19170  PhD Urša Pečar Fonović  Pharmacy  Researcher  2019 - 2024  145 
29.  36596  PhD Milica Perišić Nanut  Biotechnical sciences  Researcher  2019 - 2024  147 
30.  32035  PhD Anja Pišlar  Biotechnology  Researcher  2019 - 2024  171 
31.  51651  PhD Tina Vida Plavec  Biotechnology  Researcher  2019 - 2024  52 
32.  26507  PhD Jure Pohleven  Biochemistry and molecular biology  Researcher  2023 - 2024  75 
33.  37481  PhD Mateja Prunk  Biotechnology  Researcher  2019 - 2021  53 
34.  30887  PhD Anja Pucer Janež  Pharmacy  Researcher  2019 - 2020  59 
35.  29603  PhD Matjaž Ravnikar  Pharmacy  Researcher  2019  71 
36.  15813  PhD Boris Rogelj  Neurobiology  Researcher  2019 - 2024  412 
37.  23576  PhD Jerica Sabotič  Biochemistry and molecular biology  Researcher  2019 - 2021  323 
38.  54785  Katja Schoss  Pharmacy  Junior researcher  2020 - 2024  31 
39.  51713  PhD Emanuela Senjor  Biotechnology  Researcher  2019 - 2024  55 
40.  19786  Majda Sirnik    Technical associate  2019 - 2023 
41.  57022  PhD Spase Stojanov  Biotechnology  Researcher  2022 - 2024  20 
42.  15600  MSc Maja Šimaga    Technical associate  2019 - 2024 
43.  38850  PhD Nives Škorja Milić  Neurobiology  Researcher  2023 - 2024  18 
44.  55802  Petra Štravs  Biotechnology  Junior researcher  2021 - 2024  13 
45.  07849  PhD Borut Štrukelj  Biochemistry and molecular biology  Researcher  2019 - 2024  1,128 
46.  52419  PhD Abida Zahirović  Biotechnology  Researcher  2020 - 2024  37 
47.  58035  Ana Zupančič  Pharmacy  Junior researcher  2023 - 2024 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,412 
2.  0106  Jožef Stefan Institute  Ljubljana  5051606000  91,855 
Cancer, neurodegenerative and immune diseases represent a great health and social burden for our society. Due to prolongation of life expectancy the burden of these predominantly  age-related diseases is anticipated to be even greater in the future. To avoid the collapse of the health care system, new, more effective therapy strategies are urgently needed. Our aim is to investigate molecular mechanisms leading to pathological processes and to identify new potential targets for development of new drugs and treatments. In particular, we will address the role of proteolytic enzymes in tumor progression, anti-cancer immune response and neuroinflammation, intra-cellular signaling of RNA/protein interactors in neurological disorders, innovative delivery systems in the treatment of chronic inflammatory diseases and cancer, and mechanisms controlling allergies and autoimmune disorders. A common biotechnological platform will enable target screening, validation, modulation and preclinical testing in cell and animal models for different pathologies. Further, target inactivation and manipulation will be possible by applying peptidase inhibitors, genetically modified food grade bacteria, peptide mimotopes and various tools capable of down-regulating the expression of target proteins. Our goal is to prevent tumor invasion and metastasis, to enhance antitumor immune response by activating cytotoxic NK and T cells, to eliminate colorectal tumors by cytokine binders carried by lactic acid bacteria and to inactivate allergens and autoantibodies by peptide mimotopes. Also, we will clarify the mechanisms of post transcriptional modifications of RNA, which seem to be crucial in progression of Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia. Our research will sharpen insights into complex mechanism of pathological processes providing new solutions for patients’ treatment in order to improve the outcome of the disease and their quality of life. Our results are relevant also for the economic development of our society providing new biotechnological products with high added value interesting for companies in the field of biotechnology, biomedicine and pharmacy or for establishment of a new company. Finally, the gained new knowledge will contribute to higher level of university education, and foster international collaboration with excellent groups worldwide.
Significance for science
Understanding the basic molecular mechanisms of cell function as well as disturbances causing the development and progression of cancer, neurodegenerative and immune disorders is the major preoccupation of our programme group. Besides understanding the basic mechanisms we wish to modify these processes, to identify new diagnostic and therapeutic targets and to develop new strategies to improve patient’s treatment.   In cancer we wish to improve conventional therapeutic strategies, including surgery, chemotherapy and radiotherapy. Our approach is directed against exceeded action of proteolytic enzymes through specific inhibitors which may prevent tumor invasion and metastasis and act also on de-differentiated tumor cells and tumor stem cells, enabling in this way better effectiveness of conventional chemotherapeutics. By regulating proteolytic enzymes which participate in immune response, we want to enhance anti-tumor immune response and develop new strategies for immunotherapy and cell therapy. The need for new drugs is even more evident in neurodegenerative diseases as, despite tremendous advances in neuroscience, there are no drugs that significantly improve the course of any neurodegenerative disorder. Our research is focused on discovery of new neurotrophic factors which promote protection and regeneration of neuronal cells, and and on signaling pathways, triggered by these factors. We investigate  also the importance of RNA-related processes in neurodegeneration since the etiology of neurodegenerative diseases is associated with RNA disfunction. In immune disorders we investigate the role of proteolytic enzymes in immune cell signaling. By using recombinant lactobacteria we try to neutralize inflammatory factors in chronical bowel diseases and cancer. We investigate also the causes of allergic diseases, a part of immune diseases which significantly expanded during last years. We discover the main allergens and mechanisms to impair their harmful action.
Significance for the country
Cancer, neurodegenerative and immune diseases represent the greatest burden for health systems in modern societies which increases with the longevity of the population. Improved prevention, earlier diagnosis and more effective treatment are prerequisite steps to reduce the financial burden for health systems, to improve patient’ quality of life and to enable the economic prosperity of the society. To do this, we have to understand all views of the development and progression of diseases, besides social and environmental issues the knowledge on molecular mechanisms and identification of new diagnostic and therapeutic targets is the crucial one and represents the main goal for our programme group. Furthermore, the activities of the programme group also contribute to all levels of university education providing students opportunity to prepare research, diploma, master and doctoral works. This is possible due to long term pedagogical experience the members of the programme group gained at domestic and foreign universities. The results of the programme also foster our collaboration with excellent research groups in Slovenia and worldwide.   Biotechnology, biomedicine and pharmacy constitute besides scientific also leading economic priorities and our results make possible the development of new technologies and products, which are economically interesting for pharmaceutical and biotechnological companies. The scientific knowledge arising from top class research in this field, may result in products with high added value increasing the competitiveness of companies in Slovenia and Europe. The experience of the programme group on applicable research and patent protection and established co-operation with industrial partners guarantee successful transfer of our results to users in industry and clinics.
Most important scientific results Interim report
Most important socioeconomically and culturally relevant results Interim report
Views history